The increasing adoption of AI, generative AI, analytics, and industry-specific solutions across drug development, commercialization, and regulatory compliance is driving the rapid growth of digital services in the life sciences sector. Enterprises are turning to these technologies to improve operational resilience, accelerate time-to-market, and enhance customer and patient experiences. To meet this demand, providers are expanding their portfolios with domain expertise, industry-specific IP, data platforms, and centers of excellence, while also positioning themselves as end-to-end transformation partners by collaborating with enterprises to co-develop scalable solutions. This compendium provides detailed and fact-based snapshots of 35 life sciences digital service providers featured on Everest Group’s Life Sciences Digital Services PEAK Matrix®. Each provider profile offers a comprehensive view of its service focus, key IP/solutions, domain investments, and case studies. The study enables buyers to make informed sourcing decisions while allowing providers to benchmark themselves against competitors.

AI’s rapid evolution is revolutionizing the life sciences sector. After significant generative AI-enabled advances, enterprises are now witnessing the rise of agentic AI – autonomous systems capable of independent decision-making and action execution. However, many life sciences organizations grapple with legacy decision-making processes, fragmented data ecosystems, and innovation debt that hinder their competitive advantage. This report explores the strategic significance of agentic AI adoption, highlighting lessons learned from generative AI integration and detailing the unique opportunities and challenges associated with deploying autonomous AI systems. Key findings from industry surveys reveal gaps in readiness, data quality issues, regulatory complexities, and organizational readiness that enterprises must address. The report further delves into best practices to integrate agentic AI, including establishing robust governance frameworks, securing executive sponsorship, upskilling workforces, and conducting focused pilot programs. It highlights that leading organizations distinguish themselves by demonstrating the confidence to trust autonomous AI to drive outcomes once considered beyond reach.

Life sciences enterprises are reassessing how they engage with healthcare professionals and patients amid growing emphasis on hybrid commercial models and personalized experiences. This shift is prompting greater interest in next-generation Customer Engagement Platforms (CEPs) that offer functionality beyond traditional systems, including real-time insights, dynamic content management, and omnichannel engagement. However, legacy systems, data silos, and fragmented customer experiences still pose challenges. To overcome these barriers, life sciences companies are partnering with specialized CEP providers to develop differentiated solutions that improve engagement, operational efficiency, and data-driven decision-making. In this report, we assess 27 next-generation CEP providers. The report enables buyers to choose the best-fit provider based on their sourcing considerations and empowers providers to benchmark themselves against their peers.

Life sciences enterprises are expanding their use of Veeva Vault across regulated functions, including clinical operations, regulatory information management, quality systems, promotional content management, and CRM. As adoption moves beyond single modules to integrated, cross-Vault deployments, the need for capable service partners has intensified. Enterprises are seeking providers that can support platform-led transformation, manage evolving compliance needs, and deliver automation and innovation at scale. This PEAK Matrix® report evaluates 35 providers delivering Veeva services across the global life sciences landscape. It assesses how these providers are enabling value realization through consulting, implementation, migration, maintenance, and accelerator-led delivery. By assessing providers across dimensions such as market adoption, innovation, and delivery footprint, the report helps enterprise buyers identify the right strategic partners for their Veeva services.

Life sciences commercial teams are facing tighter budgets, faster launch cycles, and growing pressure to prove ROI from every investment and engagement. In this high-stakes environment, a new breed of specialist providers is stepping up, reshaping the commercial services landscape with targeted technology, therapeutic-area expertise, modular IP, and AI-enabled innovation designed for speed and precision. Unlike broad-based integrators, these specialists bring targeted solutions built for complexity in areas such as oncology, rare diseases, and specialty care, which is now essential. By blending therapeutic insights with smart tech and agile delivery, they’re helping sales, marketing, and launch teams move faster, make sharper decisions, and unlock value across the commercial value chain. Watch Everest Group experts as they explored how life sciences commercial services specialists are outpacing traditional integrators. As life sciences enterprises evaluate their provider portfolios, this session offered timely insights on how specialists compete – and often outperform – larger integrators on agility, depth, and commercial impact.

The life sciences industry is undergoing rapid digital transformation, fueled by the need for greater agility, regulatory compliance, and patient-centric operations. Enterprise platforms such as SAP, Oracle, and Salesforce have evolved from back-end systems of record to strategic innovation enablers, powering R&D, strengthening supply chains, and enhancing commercial effectiveness. However, challenges remain, as many organizations still operate fragmented legacy systems, struggle with complex migrations, and navigate the trade-offs between global standardization and local compliance. To address these needs, providers are investing in industry-specific accelerators, compliance-ready architectures, and intelligent automation capabilities. They are strengthening their expertise across SAP, Oracle, and Salesforce platforms, while also expanding AI/ML offerings to drive more proactive, insights-led operations. In this report, we assess 20 life sciences enterprise platform providers and position them on Everest Group’s PEAK Matrix®, a composite index of distinct metrics related to the providers’ capabilities and market impact. The study will enable buyers to choose the best-fit provider based on their sourcing considerations, while providers will be able to benchmark their performances against each other. Scope Industry: life sciences Geography: global Services: life sciences enterprise platform services Contents In this report, we examine: The provider landscape for life sciences enterprise platform services Life sciences enterprise platform providers on several capabilities and market success-related dimensions

Life sciences enterprises are embracing digital technologies to navigate the growing complexities in drug development, commercialization, and regulatory compliance. As economic pressures and competitive dynamics intensify, organizations are turning to digital services to improve operational resilience and achieve faster time-to-market. Providers are responding with targeted investments in AI / generative AI, data platforms, and industry-specific solutions to meet enterprise demands across the life sciences value chain. This PEAK Matrix® report offers a detailed evaluation of 35 providers delivering digital services in the life sciences sector, including biopharmaceutical, medical device, and others. It examines how these providers are enabling transformation through scalable solutions, co-innovation models, and differentiated capabilities. By assessing providers across dimensions such as market adoption, innovation, and delivery footprint, the report helps enterprise buyers identify the right strategic partners for their digital agendas. Scope Industry: life sciences (biopharmaceutical, medical devices, and others) Service: digital services Geography: global Contents In this report, we offer: Providers’ evaluations The evaluation scope Market trends Provider landscape analysis Key buyer considerations and takeaways Memberships Life Sciences Information Technology Sourcing and Vendor Management

Life sciences companies must engage customers effectively to drive business success through differentiated experiences. Hybrid commercial models require seamless, personalized interactions across channels to serve healthcare providers and patients. Advanced Customer Engagement Platforms (CEPs) go beyond traditional CRM systems to deliver real-time insights, dynamic content management, and omnichannel engagement. However, legacy systems, data silos, and fragmented customer experiences still pose challenges. To overcome these barriers, life sciences companies are partnering with specialized CEP providers to develop differentiated solutions that improve engagement, operational efficiency, and data-driven decision-making. In this research, we assess 27 providers featured on the Life Sciences CEP PEAK Matrix®. The study will enable buyers to choose the best-fit provider based on their sourcing considerations, while providers will be able to benchmark their performance against each other. Scope Industry: life sciences Geography: global The assessment is based on Everest Group’s annual RFI process for the calendar year 2024, interactions with leading life sciences CEP providers, client reference checks, and an ongoing analysis of the life sciences CEP market Contents In this report, we examine: The CEP provider landscape 27 life sciences CEP providers on several capability- and market success-related dimensions Memberships Life Sciences Information Technology Sourcing and Vendor Management

Drug development is a complex, time-consuming, and expensive process. The average cost to develop a new drug has increased from US$1.3 million in 2013 to US$2.3 billion in 2022. This cost increase poses a significant challenge for life sciences enterprises, especially considering that the Food and Drug Administration approves only about 12% of drugs entering clinical trials. The current scenario is not ideal, and life sciences enterprises must prioritize making their drug development processes sustainable in the long term. As the industry faces rising development costs and shrinking research and development returns, gen AI-led digital transformation has become a top priority. Gen AI is revolutionizing the life sciences value chain with use cases in drug development, clinical development, manufacturing, and sales and marketing. In this viewpoint, we share insights and our perspective on gen AI’s impact on the life sciences industry. Scope Industry: pharmaceutical Geography: global Contents In this report, we: Examine current gen Al adoption in the life sciences industry Analyze key gen AI use cases and their potential benefits Evaluate gen Al’s impact on enterprises and technology and service providers Assess best practices and challenges for successful gen AI implementation Membership(s) Life Sciences Information Technology Sourcing and Vendor Management

The life sciences industry is transforming significantly, driven by rapid technology advances and evolving customer expectations. In this dynamic landscape, commercial technology specialists are emerging as key players, offering innovative solutions across omnichannel engagement, intelligence, and content and learning management. These specialists are pivotal in helping life sciences companies navigate the modern market’s complexities, ensuring they remain competitive and relevant. In response, life sciences enterprises are increasingly turning to commercial technology specialists who bring a sophisticated understanding of advanced technologies such as AI, ML, and big data analytics, as well as expertise in a niche domain within the commercial technology value chain. These specialists are driving innovation by integrating these advanced capabilities into existing frameworks and developing new platforms that leverage a focused approach and also support cohesive commercial strategies. In this report, we assess specialists that offer proprietary life sciences commercial technology solutions, focusing on their core capabilities and market impact. We present an assessment and detailed profiles of trailblazers. Scope Industry: life sciences (biopharmaceuticals and medical devices) Geography: global Contents This report studies: Key trends shaping the life sciences commercial technology market Major adoption drivers for life sciences enterprises Enterprise-sourcing criteria for commercial technology Trailblazers, i.e., 23 leading life sciences commercial technology specialists Membership(s) Life Sciences Information Technology Life Sciences Commercial Technologies Sourcing and Vendor Management